Murat Tutanc

Murat Tutanc

Auto-generated profile, based on publicly available information

Murat Tutanc

Mustafa Kemal Üniversitesi Tayfur Ata Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Hatay, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2011 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
PDF file
MTM Tutanc
M Tutanc
Vefik ARICAVefik ARICA
Vefik ARICA
NYN Yılmaz
N Yılmaz
ANA Nacar
A Nacar
IZI Zararsiz
I Zararsiz
ENE Nacar
E Nacar
Aim: In cyclosporin-A (CsA)-induced toxicity, oxidative stress has been implicated as a potential responsible mechanism. Therefore, we aimed to investigate the protective role of erdosteine against CsA-induced nephrotoxicity in terms of tissue oxidant/antioxidant parameters and light microscopy in rats. Materials and methods: Wistar albino rats were randomly separated into four groups. Group 1 rats treated with sodium chloride served as the control, group 2 rats were treated with CsA, group 3 with CsA plus erdosteine, and group 4 with erdosteine alone. Animals were killed and blood samples were analyzed for blood urea nitrogen (BUN), serum creatinine (Cr), uric acid (UA), total protein (TP), and albumin (ALB) levels. Kidney sections were analyzed for malondialdehyde (MDA) and nitric oxide (NO) levels and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities, as well as for histopathological changes. Results: In the CsA group, MDA, GSH-Px, BUN, and Cr levels were increased. The TP and ALB levels were decreased. These changes had been improved by erdosteine administration. Other biochemical parameters did not show any significant change. Conclusion: These results indicate that erdosteine produces a protective mechanism against CsA-induced nephrotoxicity and suggest a role of oxidative stress in pathogenesis.

1 December 2019 in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
Verified
Journal Article
Closed access
MKMuhammet Furkan Korkmaz
Muhammet Furkan Korkmaz
MBMuharrem Bostancı
Muharrem Bostancı
MTMurat Tutanç
Murat Tutanç

10 September 2014 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
MCMehmet N. Cizmeci
Mehmet N. Cizmeci
DADemet Alagoz
Demet Alagoz
MAMehmet I. Avsar
Mehmet I. Avsar
GAGulten Alis
Gulten Alis
MTMurat Tutanc
Murat Tutanc

17 September 2019 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
MKMuhammet Furkan Korkmaz
Muhammet Furkan Korkmaz
MTMurat Tutanç
Murat Tutanç
MBMuharrem Bostancı
Muharrem Bostancı
MKMerve Korkmaz
Merve Korkmaz
TSTuna Ercan Salihoğlu
Tuna Ercan Salihoğlu

23 August 2013 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
MTMurat Tutanc
Murat Tutanc
ISIbrahim Silfeler
Ibrahim Silfeler
TOTumay Ozgur
Tumay Ozgur
VMVicdan Koksaldi Motor
Vicdan Koksaldi Motor
AKAhmet Ibrahim Kurtoglu
Ahmet Ibrahim Kurtoglu
Blastocystis hominis (B. hominis) is a parasite that often causes gastrointestinal symptoms in patients with immune deficiency and has a controversial pathogenicity in healthy people, although some symptoms are reported outside of the gastrointestinal system in healthy persons. Henoch-Schönlein Purpura (HSP) vasculitis is an acute autoimmune disease characterised by IgA storage of small vessels that is believed to include infectious factors in its aetiology. A 30-month follow-up with a boy diagnosed with HSP being treated with steroid therapy showed that he had recurrent symptoms within two days, and B. hominis was detected in the faecal analysis. His symptoms including rash, abdominal pain, and arthritis improved after treatment with steroid and co-trimaksazol. This paper is the first to present a case of HSP associated with B. hominis.

3 January 2019 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
IVIpek Guney varal
Ipek Guney varal
SMSenay Mengi
Senay Mengi
PDPelin Dogan
Pelin Dogan
MTMurat Tutanc
Murat Tutanc
MBMuharrem Bostancı
Muharrem Bostancı
MCMehmet N. Cizmeci
Mehmet N. Cizmeci
Objective: Preterm infants are prone to increased bilirubin burden and display adverse outcomes if left unmonitored; therefore, predicting an increased bilirubin production is of paramount importance. Methods: We aimed to evaluate carboxyhemoglobin (COHb) levels in moderate (GA: 320/7–336/7) and late preterm (GA: 340/7–366/7) infants to assess whether this molecule could be used as an early predictor of phototherapy requirement. Results: A total of 221 infants were enrolled in the study. On admission, carboxyhemoglobin levels of infants who received phototherapy were significantly higher than that of infants who did not require this treatment, and this difference persisted in the consecutive hours (median (min–max): 1.2% (0.3–1.7) versus 0.8% (0.4–1.1); p < .001). The initial and consecutive COHb levels showed positive correlation (r = 0.77, p < .001). In the post-hoc analysis, direct antiglobulin test positivity significantly affected phototherapy requirement (p < .001). Receiver operating characteristics analysis showed that a COHb level of ≥0.95% was found to have a sensitivity of 90% and a specificity of 88%. Multinomial logistic regression analysis demonstrated that high COHb levels on admission significantly increased the likelihood of phototherapy requirement when adjusted for covariants (adjusted odds ratio: 2.2; 95% confidence interval: 1.4–3.5; p < .001). Conclusion: Carboxyhemoglobin measurement can be simply used to predict preterm infants who will require phototherapy.